Literature DB >> 8394483

Serum interleukin-2 receptor levels in Hodgkin disease and other solid tumors of childhood.

C H Pui1, M Hudson, X Luo, J Wilimas, W Evans, W M Crist.   

Abstract

Serum levels of interleukin-2 receptor (IL2R) were determined in children with newly diagnosed Hodgkin disease (n = 68), Wilms tumor (n = 20), osteosarcoma (n = 18), rhabdomyosarcoma (n = 18), or Ewing sarcoma (n = 15). Measurements of soluble IL2R were positively correlated with disease stage in Hodgkin disease but not in other tumors. Very high levels of soluble IL2R (> or = 5000 U/ml) were significantly associated with a poorer treatment outcome in Hodgkin disease (p = 0.006) and retained significance in a multivariate analysis (p = 0.03). The addition of soluble IL2R measurements to existing prognostic models may improve risk assignment in children with Hodgkin disease.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8394483

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  7 in total

1.  Cytokines : as useful Prognostic Markers in Lymphoma Cases.

Authors:  G S Chopra; P G Chitalkar; M P Jaiprakash
Journal:  Med J Armed Forces India       Date:  2011-07-21

2.  The serum levels of soluble interleukin-2 receptor alpha and lactate dehydrogenase but not of B2-microglobulin correlate with selected clinico-pathological prognostic factors and response to therapy in childhood soft tissue sarcomas.

Authors:  Ewa Bien; Malgorzata Rapala; Malgorzata Krawczyk; Anna Balcerska
Journal:  J Cancer Res Clin Oncol       Date:  2009-08-20       Impact factor: 4.553

3.  Possible clinical significance of serum soluble interleukin-2 receptor level in primary bone lymphoma: two case reports.

Authors:  Hiroki Yabe; Hironori Ueno; Kensuke Ochi; Hideo Morioka; Hiroo Yabe; Chihiro Terai
Journal:  Case Rep Oncol       Date:  2011-03-04

4.  Defining the Inflammatory Plasma Proteome in Pediatric Hodgkin Lymphoma.

Authors:  Jennifer E Agrusa; Brooks P Scull; Harshal A Abhyankar; Howard Lin; Nmazuo W Ozuah; Rikhia Chakraborty; Olive S Eckstein; Nitya Gulati; Elmoataz Abdel Fattah; Nader K El-Mallawany; Rayne H Rouce; ZoAnn E Dreyer; Julienne Brackett; Judith F Margolin; Joseph Lubega; Terzah M Horton; Catherine M Bollard; M Monica Gramatges; Kala Y Kamdar; Kenneth L McClain; Tsz-Kwong Man; Carl E Allen
Journal:  Cancers (Basel)       Date:  2020-12-02       Impact factor: 6.639

5.  Proteomic Exploration of Plasma Exosomes and Other Small Extracellular Vesicles in Pediatric Hodgkin Lymphoma: A Potential Source of Biomarkers for Relapse Occurrence.

Authors:  Ombretta Repetto; Federica Lovisa; Caterina Elia; Daniel Enderle; Filippo Romanato; Salvatore Buffardi; Alessandra Sala; Marta Pillon; Agostino Steffan; Roberta Burnelli; Lara Mussolin; Maurizio Mascarin; Valli De Re
Journal:  Diagnostics (Basel)       Date:  2021-05-21

Review 6.  Pediatric Hodgkin lymphoma: biomarkers, drugs, and clinical trials for translational science and medicine.

Authors:  Poonam Nagpal; Mohamed R Akl; Nehad M Ayoub; Tatsunari Tomiyama; Tasheka Cousins; Betty Tai; Nicole Carroll; Themba Nyrenda; Pritish Bhattacharyya; Michael B Harris; Andre Goy; Andrew Pecora; K Stephen Suh
Journal:  Oncotarget       Date:  2016-10-11

7.  Proteomic Profiles and Biological Processes of Relapsed vs. Non-Relapsed Pediatric Hodgkin Lymphoma.

Authors:  Ombretta Repetto; Valli De Re; Lara Mussolin; Massimo Tedeschi; Caterina Elia; Maurizio Bianchi; Salvatore Buffardi; Alessandra Sala; Roberta Burnelli; Maurizio Mascarin
Journal:  Int J Mol Sci       Date:  2020-03-22       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.